PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for ...

PTC Inc. (NASDAQ:PTC) is among the most profitable software stocks to buy now. On February 9, TheFly reported that BofA reduced its price target on PTC Inc. (NASDAQ:PTC) to $172, down from $190, and ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...

PTC Inc. (NASDAQ:PTC) Q1 2026 Earnings Call Transcript February 4, 2026 PTC Inc. beats earnings expectations. Reported EPS is $119797.12, expectations were $1.59. Operator: Good evening, ladies and ...

PTC Inc. PTC is scheduled to report first-quarter fiscal 2026 results on Feb. 4, after market close. For the quarter, PTC anticipates revenues between $600 million and $660 million. Non-GAAP EPS is ...

DENVER (KDVR) — The Colorado Department of Revenue revealed on Wednesday how much eligible Coloradans can receive through its PTC Rebate Program and unveiled a new tax credit for Coloradans with ...

PTC Inc. (PTC) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.98 per share a year ago. These figures are ...

Autodesk (NASDAQ:ADSK) is no longer considering an acquisition of Boston-based software company PTC (NASDAQ:PTC), Bloomberg News reported, citing people with knowledge of the matter. Autodesk has ...

PTC Therapeutics reported a phase 2 win for its Novartis-partnered Huntington's disease candidate. But the readout failed to convince investors, who wiped almost 20% off PTC’s share price amid doubts ...